This is a working overview of preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-03 and is reviewed periodically as new material appears.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
ketogenesis The production of ketone bodies via the metabolic decomposition of fatty acids or ketogenic amino acids, an exergonic process which is used to supply energy to certain tissues during periods of carbohydrate and protein insufficiency.
Phylogenetic reconstruction and ancestral state reconstruction proceed by assuming that evolution has occurred without convergence. Convergent patterns may, however, appear at higher levels in a phylogenetic reconstruction, and are sometimes explicitly sought by investigators. The methods applied to infer convergent evolution depend on whether pattern-based or process-based convergence is expected. Pattern-based convergence is the broader term, for when two or more lineages independently evolve patterns of similar traits. Process-based convergence is when the convergence is due to similar forces of natural selection.
{\displaystyle K={\frac {\prod _{k}{a_{k}}^{m_{k}}}{\prod _{j}{a_{j}}^{n_{j}}}}={\frac {\prod _{k}\left([\mathrm {A} _{k}]\gamma _{k}\right)^{m_{k}}}{\prod _{j}\left([\mathrm {A} _{j}]\gamma _{j}\right)^{n_{j}}}}={\frac {\prod _{k}[\mathrm {A} _{k}]^{m_{k}}}{\prod _{j}[\mathrm {A} _{j}]^{n_{j}}}}\times {\frac {\prod _{k}{\gamma _{k}}^{m_{k}}}{\prod _{j}{\gamma _{j}}^{n_{j}}}}={\frac {\prod _{k}[\mathrm {A} _{k}]^{m_{k}}}{\prod _{j}[\mathrm {A} _{j}]^{n_{j}}}}\times \Gamma }
Other sources have defined deficiency as less than 25 nmol/L, insufficiency as 30–50 nmol/L and a level for "optimal" intake remains controversial and under research, as of 2026. Part of the controversy is because studies have reported differences in serum levels of 25(OH)D between ethnic groups, with studies pointing to genetic as well as environmental reasons behind these variations. African-American populations have lower serum 25(OH)D than their age-matched white population, but at all ages have superior calcium absorption efficiency, a higher bone mineral density, and as elderly, a lower risk of osteoporosis and fractures. Using the 25(OH)D assay as a screening tool of the generally healthy population to identify and treat individuals is considered not as cost-effective as a government-mandated fortification program. Instead, there is a recommendation that testing should be limited to those showing symptoms of vitamin D deficiency or who have health conditions known to cause vitamin deficiency.
== Chemistry == Crisaborole (chemical name: 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile) is a member of the class of benzoxaboroles characterized by the presence of a boronic acid hemiester with a phenolic ether and a nitrile. Crisaborole crystallizes into two polymorphs that differ in the conformation of the oxaborole ring. A cocrystal with 4,4'-bipyridine has been prepared and studied by X-ray crystallography.
Sources: en.wikipedia.org
Ketamine is the most widely anesthetic agent used for longer duration operations. After an intravenous therapy, which is about 2.2 mg/kg, mixed with the 1.1 mg/kg xylazine the half-life of xylazine is approximately 66 minutes and the clearance is around 31 mL/kg/min when patients are halothane-anesthetized. If only managing the xylazine and ketamine, the terminal half-life will be 42 minutes and its clearance will be 27 mL/kg/min. When the CRI of ketamine is kept stable for an hour at 2.4 mg/kg/h, the terminal half-life will be 46 minutes and the clearance will be 32 mL/kg/min.
Dephosphorylation is commonly done using calf-intestinal alkaline phosphatase (CIAP) which removes the phosphate group from the 5′ end of digested DNA, but note that CIAP is not easy to inactivate and can interfere with ligation without an additional step to remove the CIAP, thereby resulting in failure of ligation. CIAP should not be used in excessive amount and should only be used when necessary. Shrimp alkaline phosphatase (SAP) or Antarctic phosphatase (AP) are suitable alternative as they can be easily inactivated.
== Treatment == The primary treatment for urethral diverticulum is surgical. In women, the surgery is conducted transvaginally, usually when there is no acute inflammation to better aid dissection of the delicate tissues.
Katja Becker (born 7 March 1965, also known as Katja Becker-Brandenburg in some older publications) is a German physician and biochemist who has been serving as the president of the German Research Foundation (DFG) since 2020. She had previously been the organization's vice president from 2014 to 2019. From 2009 to 2012 Becker was the vice president for research at Justus Liebig University in Giessen, Germany. From 2015 to 2017 she was a German representative on the scientific committee of the European Cooperation in Science and Technology (COST).
== Decay == Uranium-235 is an alpha emitter, producing thorium-231. Uranium-235 is the main progenitor of the actinium series, one of the principal actinide decay chains, as it is the longest-lived and sole primordial nuclide (aside from the final end product, lead-207). Beginning with naturally occurring uranium-235, this series includes isotopes of astatine, bismuth, francium, lead, polonium, protactinium, radium, radon, thallium, and thorium, all of which are present in natural uranium sources. The decay proceeds as (only main decay branches shown):
Sources: en.wikipedia.org
Tenkaonian Goren Nashi (テンカオ星人ゴレン・ナシ, Tenkao Seijin Goren Nashi) and Tenkaonian Yam Tomukun (テンカオ星人ヤム・トムクン, Tenkao Seijin Yamu Tomukun): Namunan's partners of the same species who are killed by Chou San. Goren Nashi is voiced by Seiji Fujita (藤田 清二, Fujita Seiji), who also portrays his human form; Yam Tomukun is portrayed by Minoru Nanaeda (七枝 実, Nanaeda Minoru). Mikean Clord (マイク星人クロード, Maiku Seijin Kurōdo): A vine-themed criminal from Planet Mike who is charged with several counts of mass murder and inhuman experimentation stemming from his stealing young women's nutrients to cure his sister Teresa, who is dating Hoji. Despite learning of Clord's goal and being initially torn over allowing him to continue, Hoji ultimately deletes him before he can kill another group of young women. Clord is voiced by Yuuki Tsujimoto (辻本 祐樹, Tsujimoto Yūki), who also portrays his human form. Aladonian Gyanjava (アラドン星人ギャンジャバ, Aradon Seijin Gyanjaba): A cricket-themed bank robber from Planet Aladon who is charged with burglary and child abduction, having killed Yaako's parents to take advantage of her natural ability to manipulate locks. After requesting Agent Abrella's help to access the Deka Base's systems, Yaako betrays Gyanjava and helps the Dekarangers foil his latest robbery. Gyanjava dons a Muscle Gear to evade capture and judgement before piloting a Kaijuki called Cannon Gladiator 4 (キャノングラディエーター4, Kaijūki Kyanon Guradiētā Fō) to crush the Dekarangers, only to be thwarted and judged by Deka Bike Robo.
Using Mendeleev's nomenclature for unnamed and undiscovered elements, nihonium would be known as eka-thallium. In 1979, IUPAC published recommendations according to which the element was to be called ununtrium (with the corresponding symbol of Uut), a systematic element name as a placeholder, until the discovery of the element is confirmed and a name is decided on. The recommendations were widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, but were mostly ignored among scientists in the field, who called it "element 113", with the symbol of E113, (113), or even simply 113. Before the JWP recognition of their priority, the Japanese team had unofficially suggested various names: japonium, after their home country; nishinanium, after Japanese physicist Yoshio Nishina, the "founding father of modern physics research in Japan"; and rikenium, after the institute. After the recognition, the Riken team gathered in February 2016 to decide on a name. Morita expressed his desire for the name to honour the fact that element 113 had been discovered in Japan. Japonium was considered, making the connection to Japan easy to identify for non-Japanese, but it was rejected as Jap is considered an ethnic slur. The name nihonium was chosen after an hour of deliberation: it comes from Nihon (日本), one of the two Japanese pronunciations for the name of Japan.
=== Kodesomes === Kodesomes are liposomes that have been decorated with FSL Kode constructs. These have been used to deposit FSL constructs onto microplates to create diagnostic assays. They also have the potential for therapeutic use.
== Veterinary use == Intra-abdominal adhesions are common in rabbits following surgery. Verapamil can be given postoperatively in rabbits which have suffered trauma to abdominal organs to prevent formation of these adhesions. Such effect was not documented in another study with ponies.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.